Novo Nordisk’s slimming pill in development meets safety profile
Bankinter | Phase II trial of amucretin-based slimming pill has met targets. Patients lost 13% of their weight in 12 weeks. The drug candidate has the same gastrointestinal side effects, such as nausea and vomiting, as other incretin-based slimming agents. The company will present the study results next week at the European Association for the Study of Diabetes congress. Novo Nordisk will decide in 2025 whether to advance to Phase…